Michael Cruse - RPHM Old Chief Officer
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Insider
Michael Cruse is Chief Officer of RPHM Old
| Age | 52 |
| Phone | 858 283 0280 |
| Web | https://reneopharma.com |
RPHM Old Management Efficiency
The company has return on total asset (ROA) of (0.3372) % which means that it has lost $0.3372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.54) %, meaning that it created substantial loss on money invested by shareholders. RPHM Old's management efficiency ratios could be used to measure how well RPHM Old manages its routine affairs as well as how well it operates its assets and liabilities.RPHM Old currently holds 973 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. RPHM Old has a current ratio of 15.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about RPHM Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Adaptive Biotechnologies Corp | 50 | |
| Elaine JD | Summit Therapeutics PLC | 63 | |
| Christopher Hite | Royalty Pharma Plc | 57 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Daniel Hicklin | Werewolf Therapeutics | 61 | |
| Ann Lee | Prime Medicine, Common | 63 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Igor MD | Celcuity LLC | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Badreddin Edris | Edgewise Therapeutics | 38 | |
| Randi MD | Werewolf Therapeutics | 69 | |
| Howard Horn | Vir Biotechnology | 46 | |
| Mark Dmytruk | Ginkgo Bioworks Holdings | 54 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| Divya Chari | Summit Therapeutics PLC | 57 | |
| Gabriel BA | Immix Biopharma | 38 | |
| Johanna FriedlNaderer | Vir Biotechnology | 56 | |
| MBA MD | Immix Biopharma | 49 | |
| Joshua Kazam | Kronos Bio | 48 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 |
RPHM Old Leadership Team
Elected by the shareholders, the RPHM Old's board of directors comprises two types of representatives: RPHM Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RPHM. The board's role is to monitor RPHM Old's management team and ensure that shareholders' interests are well served. RPHM Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RPHM Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Flesher, CEO President | ||
| Alejandro MD, Chief Officer | ||
| Ashley JD, Chief Officer | ||
| Wendy MBA, Consultant | ||
| Vineet Jindal, Consultant | ||
| Michael Cruse, Chief Officer | ||
| Jennifer Lam, Principal Officer | ||
| Lynn Purkins, Senior Development | ||
| Michael Grey, Founder Chairman |
RPHM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RPHM Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in RPHM Stock
If you are still planning to invest in RPHM Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RPHM Old's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |